A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells

Riki Toita, Masaharu Murata, Kana Abe, Sayoko Narahara, Jing Shu Piao, Jeong Hun Kang, Makoto Hashizume

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

Herein, we report the preparation of genetically engineered protein cages (HspG41C-SP94), taken up selectively by human hepatocellular carcinoma (HCC) cells. An engineered protein cage–doxorubicin (DOX) conjugate was as cytotoxic as free DOX against HCC cells but much less cytotoxic against normal hepatocytes.

Original languageEnglish
Pages (from-to)7442-7444
Number of pages3
JournalChemical Communications
Volume49
Issue number67
DOIs
Publication statusPublished - Jul 25 2013

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry

Fingerprint Dive into the research topics of 'A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells'. Together they form a unique fingerprint.

Cite this